CD14 and bacterial infectious disease with sepsis: Due to the intriguing functions played by both NFAT and CD14, the development of selective inhibitors targeting the calcineurin‐NFAT pathway or CD14 and their impact on LPS‐induced inflammation or bacterial sepsis has sparked great scientific interest over the years.[43, 44, 45, 46, 47, 48] As example, in vivo studies demonstrated the protective role of the calcineurin‐NFAT inhibitor CP9‐ZIZIT in reducing pulmonary edema in mice affected by acute lung injury following intranasal administration of LPS.[49] In contrast, Poli et al.